Research programme: vascular protectants - AtheroGenics

Drug Profile

Research programme: vascular protectants - AtheroGenics

Alternative Names: AGI-2048; AGI-2636; AGI-series for respiratory diseases; v-protectants

Latest Information Update: 11 May 2009

Price : $50

At a glance

  • Originator AtheroGenics
  • Class Small molecules
  • Mechanism of Action Antioxidants; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Asthma; Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Obstructive airways disease pharmacodynamics section ,
  • 14 Oct 2004 This programme is still in active development for Rheumatoid arthritis
  • 14 Nov 2003 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top